Anti-VEGF Treatment for Prevention of PDR/DME

Status: Currently enrolling

ClinicalTrials.gov Identifier: NCT02634333

Rise: Ranibizumab Injection in patients with clinically significant macular edema with center involvement secondary to Diabetes.

Condition: Diabetic Retinopathy & Diabetic Macular Edema

Study Type: Interventional

Duration: 6 years

Eligibility:

  • Ages: 18 years and older
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.